ArticlePharmacoEconomics - open2023

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal.

Paulo Martins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.